Federal Register #DEA-1748

DEA Notice: Import Registration for Cannabis-Derived Substances for Research

This opportunity concerns the Drug Enforcement Administration (DEA) notice regarding Biopharmaceutical Research Company's application to import Schedule I controlled substances for research and clinical trial purposes. - Government Buyer: - Department of Justice (DOJ), Drug Enforcement Administration (DEA) - OEM/Vendor: - Biopharmaceutical Research Company - Products Requested: - Marihuana Extract (drug code 7350) - Marihuana (drug code 7360) - Tetrahydrocannabinols (drug code 7370) - All substances are Schedule I controlled substances - Quantities: - Not specified; importation as flowering plants and cannabis derivatives - Purpose: - Analytical chemistry analyses - Research - Manufacturing of dosage forms for preclinical and clinical trials - Unique/Notable Requirements: - Importation is strictly for research and clinical trial manufacturing - No authorization for import of FDA-approved or non-approved finished dosage forms for commercial sale - No other activities for these drug codes are authorized under this registration

Description

Biopharmaceutical Research Company has applied to be registered as an importer of basic classes of controlled substances including Marihuana Extract, Marihuana, and Tetrahydrocannabinols. The company plans to import these substances as flowering plants and cannabis derivatives to support analytical chemistry analyses, research, and the manufacturing of dosage forms for preclinical and clinical trials. No other activities for these drug codes are authorized for this registration. Comments on the application must be submitted by September 24, 2026, and requests for a hearing may also be filed by this date.

View original listing